Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Raw Materials (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 11 years of Raw Materials data on record, last reported at $105.8 million in Q3 2025.

  • For Q3 2025, Raw Materials rose 74.7% year-over-year to $105.8 million; the TTM value through Sep 2025 reached $105.8 million, up 74.7%, while the annual FY2024 figure was $81.5 million, 62.76% up from the prior year.
  • Raw Materials reached $105.8 million in Q3 2025 per AMPH's latest filing, down from $106.5 million in the prior quarter.
  • Across five years, Raw Materials topped out at $106.5 million in Q2 2025 and bottomed at $40.4 million in Q1 2022.
  • Average Raw Materials over 5 years is $58.8 million, with a median of $47.9 million recorded in 2023.
  • Peak YoY movement for Raw Materials: decreased 20.63% in 2021, then surged 100.84% in 2025.
  • A 5-year view of Raw Materials shows it stood at $41.9 million in 2021, then increased by 13.75% to $47.6 million in 2022, then grew by 5.2% to $50.1 million in 2023, then skyrocketed by 62.76% to $81.5 million in 2024, then rose by 29.75% to $105.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $105.8 million in Q3 2025, $106.5 million in Q2 2025, and $103.3 million in Q1 2025.